ABIOMED, Inc. (NASDAQ:ABMD) Shares Sold by Stevens Capital Management LP

Stevens Capital Management LP reduced its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 34.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,552 shares of the medical equipment provider’s stock after selling 7,006 shares during the quarter. Stevens Capital Management LP’s holdings in ABIOMED were worth $3,530,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in ABMD. Kornitzer Capital Management Inc. KS boosted its holdings in ABIOMED by 102.1% in the second quarter. Kornitzer Capital Management Inc. KS now owns 111,366 shares of the medical equipment provider’s stock valued at $29,010,000 after purchasing an additional 56,251 shares during the last quarter. Villere ST Denis J & Co. LLC acquired a new stake in ABIOMED during the second quarter valued at approximately $61,142,000. Highstreet Asset Management Inc. raised its stake in ABIOMED by 39.0% during the second quarter. Highstreet Asset Management Inc. now owns 2,562 shares of the medical equipment provider’s stock valued at $667,000 after buying an additional 719 shares in the last quarter. KBC Group NV raised its stake in ABIOMED by 1.9% during the second quarter. KBC Group NV now owns 19,079 shares of the medical equipment provider’s stock valued at $4,970,000 after buying an additional 362 shares in the last quarter. Finally, Ascent Wealth Partners LLC raised its stake in ABIOMED by 12.7% during the second quarter. Ascent Wealth Partners LLC now owns 5,392 shares of the medical equipment provider’s stock valued at $1,404,000 after buying an additional 606 shares in the last quarter. Hedge funds and other institutional investors own 86.63% of the company’s stock.

In other news, COO David M. Weber sold 8,095 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $206.26, for a total transaction of $1,669,674.70. Following the sale, the chief operating officer now directly owns 132,913 shares in the company, valued at approximately $27,414,635.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.40% of the stock is currently owned by corporate insiders.



Several analysts have issued reports on ABMD shares. Zacks Investment Research cut ABIOMED from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. Morgan Stanley cut ABIOMED from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $325.00 to $215.00 in a research note on Thursday, August 1st. Guggenheim cut ABIOMED from a “buy” rating to a “neutral” rating in a research note on Friday, August 2nd. SunTrust Banks restated a “buy” rating and set a $340.00 price objective on shares of ABIOMED in a research note on Friday, May 3rd. Finally, William Blair restated a “buy” rating on shares of ABIOMED in a research note on Friday, August 2nd. Three analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $316.50.

Shares of ABIOMED stock traded up $0.57 on Thursday, reaching $190.70. 66,698 shares of the company were exchanged, compared to its average volume of 796,008. The stock has a 50-day moving average price of $244.53. The stock has a market capitalization of $8.70 billion, a price-to-earnings ratio of 52.97, a price-to-earnings-growth ratio of 1.69 and a beta of 0.31. ABIOMED, Inc. has a 1-year low of $181.02 and a 1-year high of $459.75.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported $1.00 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.01. The business had revenue of $207.70 million for the quarter, compared to analysts’ expectations of $210.96 million. ABIOMED had a return on equity of 19.84% and a net margin of 32.35%. The business’s quarterly revenue was up 15.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.95 EPS. Equities analysts forecast that ABIOMED, Inc. will post 4.3 earnings per share for the current year.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Read More: How Do Investors Open a Backdoor Roth IRA?

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.